TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 40 to 85 years with OBSTRUCTIVE AIRWAY DISEASES (ASTHMA AND COPD) and a forced expiratory volume (FEV1) \> 0.5.~* Patients should have a clinical indication to undergo cardiac stress test with dobutamine.~Exclusion Criteria:~* Those with pacemakers, defibrillators, functioning neural stimulator devices or other implanted electronic devices.~* Ferromagnetic cerebral aneurism clips or other intraorbital and intracranial metal.~* An allergy to Gadolinium or other severe drug allergies.~* Acute myocardial infarction within 3 months.~* Moderate or severe aortic stenosis or other significant valvular disease;~* Claustrophobia.~* High grade (2o or 3o) AV Block.~* Closed angle glaucoma.~* Participants unable to provide informed consent.~* Renal dialysis (subjects with moderate-to-severe renal impairment defined as eGFR \< 60 mL/min.~* A contraindication to receipt of dobutamine.~* Participants with known coronary artery disease will be included with the exception that patients with left main or narrowings \>50% in the distributions of the left anterior descending, circumflex, and right coronary artery will be excluded.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
- B (Type: ACTIVE_COMPARATOR): Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major depressive episode diagnosed with Diagnostic and Statistical Manual Diploma in Social Medicine-IV (DSM-IV)~* Hamilton Depression Scale (HAMD-17) ≥ 14~Exclusion Criteria:~* Any other axis I primary diagnoses except major depressive disorder~* Having serious adverse events or hypersensitivity to mirtazapine~* Having major depressive disorder prior to the first injection of interferon

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- mirtazapine (Type: EXPERIMENTAL): mirtazapine
- Supportive psychotherapy (Type: OTHER): Supportive psychotherapy will be given by a specialized psychiatrist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Different Onset Times of Treatment With Pulsed Dye Laser on Improvement of Surgical Scars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Surgical scar with minimum length of 6 cm~Exclusion Criteria:~* History of light sensitivity or photodermatoses~* History of adverse reactions to laser treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): pulsed dye laser and dynamic cooling device on the day of suture removal
- B (Type: ACTIVE_COMPARATOR): pulsed dye laser and dynamic cooling device 2 months after suture removal
- C (Type: SHAM_COMPARATOR): dynamic cooling device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Modulation as Treatment in Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute heart failure~* NYHA class III - IV.~* ejection fraction \<35~Exclusion Criteria:~* Age \<18 år or \>85 år,~* allergy~* renal failure~* recently developed brady- or tachy-arrythmias~* Serious infection~* Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease~* Recent Myocardial infarction (\<6 Weeks)~* Pulmonary Wedge pressure \>30 mm Hg~* diabetes mellitus treated with insulin~* peptic ulcer~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omacor on Triglycerides in HIV Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Triglycerides between 200 and 800~* diagnosed HIV infection~* following HAART therapy~Exclusion Criteria:~* other malignant disease~* not compliant~* allergy against fish oil~* soy or olive oil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of UPJ stenosis requiring surgical repair~* Ages 3 months to 14 years old~* Guardians give consent and the child gives assent when appropriate~* Both genders~* All racial and ethnic groups~Exclusion Criteria:~* A history of chronic pain and/or use of chronic opioids and other analgesic(s)~* If parents/patients or attending urologist request epidural analgesia or refuse to participate in the study~* Impairment of cognition/neurologic, hepatic, renal, cardiovascular, endocrine, metabolic, and/or coagulation function~* A history of any diagnosis of psychiatric disorders, including bipolar disorders by self-report or by guardian~* A recent history of illicit chemical abuse within one week prior to surgical date~* Participants known to be taking prescribed medications or over-the-counter medications known to affect pain perception such as central nervous system stimulants, hypnotics, sedatives, etc within 24 hours of planned surgical procedure

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine group (Type: ACTIVE_COMPARATOR): Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
- Normal Saline Group (Type: PLACEBO_COMPARATOR): Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An ACT-Based Physician-Delivered Weight Loss Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Only participants considered to be emotional eaters, as assessed by a score of 3.25 or higher on the Dutch Eating Behavior Questionnaire (DEBQ), were recruited for the study (van Strien, Herman, Anschutz, Engels, \& de Weerth, 2012).~Exclusion Criteria:~* Not being an emotional eater.~* Participants who did not speak, write, and read in English fluently were excluded from the study, as well as those who were pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Care (Type: ACTIVE_COMPARATOR): Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
- ACT Intervention (Type: EXPERIMENTAL): In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unresectable cancer for which there are genomic drivers with corresponding Food and Drug Administration (FDA) approved or experimental drugs available, e.g. non-small cell lung cancer; and/or patients with histologically confirmed metastatic malignancy that have failed standard treatment or cannot tolerate standard treatment as deemed by the treating physician~* Malignancy must be measureable as per appropriate guidelines~* Patients who are willing to provide a specimen for genomic sequencing~  * Preferred method:~    * Tumor cell sample available and of sufficient quantity in the Tumor Tissue Shared Resource or patients who are willing to undergo additional tissue collection for tumor genomic sequencing through FoundationOne; available specimens must have been harvested within two years to be eligible~ * Alternative method:~    * Patients who are unwilling or unable to provide a tumor tissue sample and who undergoes Guardant360 sequencing may be considered eligible by the treating physician~ * Patients who have already had their specimens sent for genomic sequencing are eligible provided they have not received their sequencing results at the time of enrollment~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2~* Absence of clinically relevant liver or kidney failure as deemed by the treating physician~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document~Exclusion Criteria:~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diminished mental capacity or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (precision medicine) (Type: EXPERIMENTAL): Patients receive treatment based on the results of their genomic sequencing analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (male and female) between 18 and 75 years~* 1 -12 month after TBI or SAH before prescreening~* Cortisol level 100-180 ng/ml after stimulation with ACTH~* Written informed consent by patient or a legally accepted representative~Exclusion Criteria:~* Pregnancy and lactation period (during study treatment)~* Concomitant or previous high-dose therapy with glucocorticoids; previous treatment with glucocorticoids will be accepted, if it has been low dose (i.e. lower than the Cushing threshold) and has been stopped at least 3 months before study participation~* Suspected or known hypersensitivity to hydrocortisone or any of its components~* Albumine less than 2,5 g/dl~* Suspected or known drug or alcohol abuse~* Planned treatment for thyroid dysfunction or a planned change in established thyroid treatment~* Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.~* Participation in another clinical trial with investigational new drugs~* Severe medical or psychiatric disease~* Change of dosage of any other drug which might influence the corticotrope axis or cognitive function (e.g. antidepressive treatment) during the last 3 weeks~* Oral contraceptives~* Severe disturbances in articulation, visual faculty or hearing~* Any elective surgery or medical treatment planned in the observation period~* Intensive Care treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo/20 mg hydrocortisone (Type: PLACEBO_COMPARATOR): Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
- 20 mg hydrocortisone/placebo (Type: ACTIVE_COMPARATOR): Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Rehabilitation of the Upper Limb After a Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years;~* Stroke hemiparesis on unilateral focal lesion dating from 4 to 10 weeks at baseline;~* Active flexion of the paretic shoulder ≥15 °;~* Average score on the modified scale of Frenchay \<5;~* Patient having agreed to sign an informed consent.~Exclusion Criteria:~* Passive extension of the paretic elbow \<120 °;~* Passive extension of the paretic wrist \<10 °;~* Cognitive dysfunction or progressive intercurrent illness making effective communication or participation in the study impossible;~* Infection, inflammation or complex regional pain syndrome of the paretic upper extremity;~* Injection of botulinum toxin to the upper limb less than 3 months old;~* Patient under safeguard of justice;~* Patient include in an other clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Conventional rehabilitation (Type: ACTIVE_COMPARATOR): 5 sessions / week of 1 hour of occupational therapy
- Robotic rehabilitation with assistance (Type: ACTIVE_COMPARATOR): 5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
- Non-assistance robotic rehabilitation (Type: ACTIVE_COMPARATOR): 5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of idiopathic Parkinson's disease~* deemed an appropriate candidate for DBS surgery~* Montreal Cognitive Assessment (MoCA) score \< 25~* Neuropsychological testing with the diagnosis of Mild Cognitive Impairment~Exclusion Criteria:~* no diagnosis of Parkinson's disease~* not appropriate for DBS surgery

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parkinson's patients with MCI (Type: ACTIVE_COMPARATOR): Procedure: deep brain stimulation surgery
- Parkinson's patients without MCI (Type: ACTIVE_COMPARATOR): Procedure: deep brain stimulation surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 70 years~* For women, effective contraception during the trial and a negative pregnancy test (urine) before enrollment~* Patients naïve to prior hepatitis C treatment~* Confirmed HCV infection, based on the presence of HCV antibodies and plasma viremia allowing a measure of the circulating viral load~* Infection with HCV genotype 1 or 4~* Intent of treatment Alfa2 pegylated IFN-/ ribavirin~Exclusion Criteria:~* HBV Infection~* HIV Infection~* Severe anemia (Hb \<7-8 g / dl)~* Renal failure (creatinine clearance \<60 ml / min)~* Taking digoxin within 6 months of starting treatment.~* Taking immunosuppressants within 6 months of starting treatment~* History of serious hypersensitivity reaction (such as anaphylactic shock or angioedema) to sitagliptin~* Patients with type I and II diabetes~* Pregnancy or absence of effective contraception~* A person deprived of liberty by judicial or administrative decision~* Living conditions-suggesting an inability to track all scheduled visits by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DPPIV Inhibition (Type: EXPERIMENTAL): The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Overload Management and Vascular Stiffness in Chronic Kidney Disease Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\>18 years old) outpatient with uncontrolled hypertension; defined as, AMBP ≥ 130/80 mmHg despite treatment~* With an estimated glomerular filtration rate (eGFR) of 15-45 ml/min/1.73 m2.~* Fluid overload of more than 5% of estimated normal ECFV, as assessed by Bio-impedance spectroscopy (we are using the Body Composition Monitor, a validated device marketed by Fresenius, Canada).~Exclusion Criteria:~* Pregnancy or lactation~* Declined informed consent~* Patients with cognitive dysfunction~* Surgery within six weeks of the study~* Patients with heart failure, atrial fibrillation, stroke, nephrotic syndrome and active auto-immune disease~* Patients with severe life-limiting comorbidities like cancer~* Patients with amputated limbs (despite the fact that the BCM device can be used if people have a unilateral amputation, the home devices measure via 2 legs).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Bio-impedance spectroscopy.~Treatment algorithm for diuretic therapy.
- Control group (Type: NO_INTERVENTION): No intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial on the Effects of Ultrasound Probe Position on Ultrasound-guided Nerve Blocks

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Right handed~* Aged 18 to 55~Exclusion Criteria:~* Any person who has prior knowledge about ultrasound imaging or regional anesthesia~* Any person who has prior experience with laparoscopy or biopsy~* Any person who has problems with depth of field or simple hand eye co-ordination task

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Parallel Probe Position (Type: None): Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
- Perpendicular Probe Position (Type: None): Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy